# Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

> **NCT04494386** · PHASE1,PHASE2 · COMPLETED · sponsor: **Restem, LLC.** · enrollment: 17 (actual)

## Conditions studied

- Covid19
- Corona Virus Infection
- SARS-CoV Infection
- ARDS
- Coronavirus

## Interventions

- **BIOLOGICAL:** Umbilical Cord Lining Stem Cells (ULSC)
- **OTHER:** Placebo (carrier control)

## Key facts

- **NCT ID:** NCT04494386
- **Lead sponsor:** Restem, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-23
- **Primary completion:** 2023-05-12
- **Final completion:** 2023-05-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04494386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04494386, "Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04494386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*